Real-world Study Of PD-1/PD-L1 Immune Checkpoint Inhibitors In The Treatment Of Triple-negative Breast Cancer

Objective to explore the short-term efficacy（ORR,DCR,PFS）and side effects of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer.Methods A retrospective analysis from September 2019 to January 2022,41 TNBC patients who treated with PD-1/PD-L1 immune checkpoint inhibitors in Hangzhou first people’s Hospital and Hangzhou Cancer Hospital,Clinical data,efficacy and side effects were collected,to analyze the short-term efficacy of ICIs in the treatment of triple negative breast cancer and draw the survival curves were performed using SPSS 25.0 software.Results A total of 41 patients with triple negative breast cancer were included in this study,including CR 0,PR 11（26.8%）,SD 12（29.3%）,PD 18（43.9%）,The objective response rate（ORR）and disease control rate（DCR）of ICIs-treated patients were 26.8%and 56.1%.The median PFS was 10 months（95%CI,6.9-13.1 months）.In the TNBC patients treated with PD-1/PD-L1 immune checkpoint inhibitors,PFS in the combined chemotherapy group was longer than that in the single immunotherapy group（P=0.03）,PFS in the PD-L1 high expression group was longer than that in the PD-L1 low expression group（P=0.046）,and PFS in the young and middle-aged group was longer than that in the elderly group（P=0.023）,but there was no significant correlation between Ki-67%expression and PFS in the patients.Conclusion PD-1/PD-L1 immune checkpoint inhibitors therapy is effective in TNBC patients,and patients with high expression of PD-L1,combined chemotherapy and young and middle-aged patients get longer PFS and better short-term efficacy,its potential predictive value may be helpful in risk stratification and treatment strategy formulation,...